Anadolu University | Turkey
Author Profile
Scopus
Orcid
Early Academic Pursuits 🎓
Prof. Dr. Mehlika Dilek Altıntop began her academic journey at İkieylül Elementary School (1991-1996) and continued at Eskişehir Anatolian High School (1996-2003). She pursued her undergraduate studies at Anadolu University, Faculty of Pharmacy (2003-2007). Following this, she completed her Master’s degree (with thesis) at Anadolu University, Graduate School of Health Sciences, Department of Pharmaceutical Chemistry (2007-2009). Her doctoral studies were also undertaken at Anadolu University, focusing on Pharmaceutical Chemistry (2009-2012).
Professional Endeavors 🏢
Dr. Altıntop’s professional career began as a Research Assistant at Anadolu University, Faculty of Pharmacy (2010-2012). She advanced to Research Assistant Doctor (2012-2014) and subsequently to Assistant Professor Doctor (2014-2015). She earned her position as Associate Professor Doctor (2015-2020) and was promoted to Professor Doctor (2020-present) at Anadolu University, Faculty of Pharmacy. Her administrative roles include serving as the Erasmus/Farabi/Mevlana Assistant Coordinator (2013-2014), Associate Director of Anadolu University Graduate School of Health Sciences (2014-2017 and 2023), and Quality Coordinator (2022-2023).
Contributions and Research Focus 🔬
Prof. Dr. Altıntop’s research predominantly focuses on pharmaceutical chemistry, medicinal chemistry, and drug development. She has made significant contributions to the synthesis and evaluation of novel compounds with therapeutic potential. Her work includes the development of dual EGFR and Akt inhibitors and small-molecule inhibitors targeting cancer therapy. She has also explored novel metabolic enzyme inhibitors and aldose reductase inhibitors.
Accolades and Recognition 🏆
Dr. Altıntop has received numerous awards for her academic and research achievements:
- Anadolu University Faculty of Pharmacy Championship Award (2007)
- Graduate Scholarship from The Scientific and Technological Research Council of Turkey (2007-2009)
- Anadolu University Science and Technology Encouragement Award (2014)
- Anadolu University Gold Article Performance Award (2015)
- Turkish Pharmacists’ Association Academy of Pharmacy Encouragement Award (2019)
- Outstanding Woman Researcher in Pharmaceutical Chemistry Award (VIWA 2021)
- ISIF'21 Silver Medal for invention (2021)
- Top Cited Article Awards (2021-2023)
Impact and Influence 🌟
Dr. Altıntop’s work has had a substantial impact on the field of pharmaceutical chemistry, particularly in the development of novel therapeutic agents for cancer and other diseases. Her role as an Associate Editor and Guest Editor in prestigious journals, as well as her involvement in international scientific committees, highlights her influence and leadership in the field.
Legacy and Future Contributions 🌐
Prof. Dr. Altıntop’s contributions continue to shape the future of pharmaceutical research and drug development. Her ongoing work in medicinal chemistry and her role in mentoring the next generation of researchers underscore her lasting legacy in advancing science and improving healthcare outcomes.
Publications
- 📜Design, Synthesis, and Biological Evaluation of a New Series of Imidazothiazole-Hydrazone Hybrids as Dual EGFR and Akt Inhibitors for NSCLC Therapy
Authors: Mehlika Dilek Altıntop, İpek Ertorun, Gülşen Akalın Çiftçi, Ahmet Özdemir
Journal: European Journal of Medicinal Chemistry
Year: 2024
- 📜Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents
Authors: Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
Journal: ACS Omega
Year: 2024
- 📜Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents
Authors: Altıntop, M.D., Cantürk, Z., Özdemir, A.
Journal: ACS Omega
Year: 2023
- 📜Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy
Authors: Erdoğan, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
Journal: ACS Omega
Year: 2023
- 📜A New Series of Hydrazones as Small-Molecule Aldose Reductase Inhibitors
Authors: Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
Journal: Archiv der Pharmazie
Year: 2023
- 📜A New Series of Thiazole-Hydrazone Hybrids for Akt-Targeted Therapy of Non-Small Cell Lung Cancer
Authors: Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
Journal: Drug Development Research
Year: 2023